Company Overview and News

KLCI gains after US equities' overnight rise

2018-10-17 theedgemarkets
KUALA LUMPUR (Oct 17): The FBM KLCI gained 3.75 points or 0.22% today with Asian shares after US equities' overnight rise.
HLFBF 3867 5819 1082 BATS 4162 2836 5246

KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

KLCI stages technical rebound, reverses earlier loss

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF

KLCI starts lower in line with frail regional markets

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI fell for the eighth day running this morning, amid frail regional sentiment.
HLFBF 3026 PBLOF 3867 5819 1082 1295 BSMAF 3034 7022 GBTKF 1818

KLCI down 2% amid regional bloodbath

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI pared some of its losses at the midday break today, having gyrated between above and below the 1,700-point level during the morning session.
UPBMF 5681 BATS 4162 2089 9334 6033 5199 PNADF 5347 1201 3867 TNABY 6888 AXXTF TNABF HIPEF PNAGF

KLCI sinks 2.75% amid regional sea of red

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI lost 2.75% at mid-morning today, tracking the sea of red across regional markets.
UPBMF 7036 5681 BATS 4162 2089 6033 5199 5139 5238 PNADF 5347 1201 3867 0900 TNABY TNABF HIPEF PNAGF 3719

KLCI tumbles 2.63%, falls below 1,700-level

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI tumbled 2.63% in early trade this morning and slipped below the crucial 1,700-point threshold , tracking widespread losses at most regional markets.
KLKBY 2445 5347 3867 TNABY UPBMF 5819 BATS 4162 TNABF 2089 3719

KLCI remains marginally lower, construction stocks fall

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI remained marginally in the negative zone, having pared much of its losses in the morning session today, against the backdrop of weaker regional markets.
SPMXF 7036 5681 5263 BATS 4162 1163 5256 7123 5199 SPMXY 5225 3026 3301 3867 1899 Q0F IHHHF HIPEF GEBHF

KLCI stays negative, falls 0.43%

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI remained in the negative zone at the midday break today, and fell 0.43% in line with the decline at regional markets.
UPBMF 5088 7113 5010 TPGVF 5202 2089 9334 6033 5199 9113 TGLVY 0143 5139 4588 PNADF 3867 0900 6888 AXXTF 2836 HIPEF PNAGF

FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

KLCI pares loss as select blue chips lend support

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI pared some of its loss at midday break today, against a backdrop of struggling regional markets.
HLFBF BRDBF 7036 1082 5681 6432 BATS 4162 7374 5256 5199 5210 1783 5029 3867 SGPBY 6888 AXXTF 5827 1902 HIPEF GEBHF 3719

KLCI falls 0.57% as China calls off trade talks with US

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF

KLCI slips 0.19% on mild profit taking

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI slipped at mid-morning and dipped 0.19% on some mild profit taking.
7052 7060 UPBMF 7036 5202 2089 6033 7123 5199 PNADF 3026 3867 0026 6645 5819 2836 1902 HIPEF PNAGF

KLCI gains 0.61%, crosses 1,800 level as regional sentiment perks up

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF

Chinese firm leads takeover for Unisem at RM3.30 per share

2018-09-13 theedgemarkets
KUALA LUMPUR: Unisem (M) Bhd's controlling shareholder John Chia and China’s Tianshui Huatian Technology Co Ltd (TSHT) are making a pre-conditional voluntary conditional takeover offer for the semiconductor firm at RM3.30 per share — a 11.11% premium over the last traded price before the announcement.
3867 7022 GBTKF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...